oxybutynin has been researched along with Depression, Involutional in 5 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Efforts to develop existing drugs into user-friendly dosage forms with a number of advantages in major depressive states, including but not limited to: sustained drug release, reduced drug dosing frequency, improved tolerance and adherence, suitability for use in diverse populations and different treatment scenarios, as well as less central nervous system side effects are required." | 2.72 | Transdermal Route: A Viable Option for Systemic Delivery of Antidepressants. ( Khanna, G; Nunez, E; Puri, A; Singh, K; Tijani, AO, 2021) |
| " Patient adherence theoretically could be improved due to ease of use and once-daily dosing when compared to oral counterparts' need for multiple daily doses." | 2.52 | A critical appraisal of the selegiline transdermal system for major depressive disorder. ( Bied, AM; Kim, J; Schwartz, TL, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tijani, AO | 1 |
| Nunez, E | 1 |
| Singh, K | 1 |
| Khanna, G | 1 |
| Puri, A | 1 |
| DelBello, MP | 1 |
| Hochadel, TJ | 1 |
| Portland, KB | 1 |
| Azzaro, AJ | 1 |
| Katic, A | 1 |
| Khan, A | 1 |
| Emslie, G | 1 |
| Nakonezny, PA | 1 |
| Mayes, TL | 1 |
| Byerly, MJ | 1 |
| Emslie, GJ | 1 |
| Bied, AM | 1 |
| Kim, J | 1 |
| Schwartz, TL | 1 |
| Cristancho, MA | 1 |
| Thase, ME | 1 |
3 reviews available for oxybutynin and Depression, Involutional
| Article | Year |
|---|---|
Transdermal Route: A Viable Option for Systemic Delivery of Antidepressants.
Topics: Administration, Cutaneous; Antidepressive Agents; Depressive Disorder, Major; Drug Delivery Systems; | 2021 |
A critical appraisal of the selegiline transdermal system for major depressive disorder.
Topics: Administration, Cutaneous; Antidepressive Agents; Depressive Disorder, Major; Drug Liberation; Human | 2015 |
Critical appraisal of selegiline transdermal system for major depressive disorder.
Topics: Administration, Cutaneous; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Selegil | 2016 |
1 trial available for oxybutynin and Depression, Involutional
| Article | Year |
|---|---|
A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
Topics: Administration, Cutaneous; Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dou | 2014 |
1 other study available for oxybutynin and Depression, Involutional
| Article | Year |
|---|---|
Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
Topics: Adolescent; Child; Depressive Disorder, Major; Female; Humans; Male; Models, Statistical; Neuroprote | 2015 |